CAMBRIDGE, Mass. – Voluntis has received clearance from the U.S. Food and Drug Administration, as well as the CE Mark, for Insulia, a device that supports the management of adult patients with Type 2 diabetes treated with basal insulin. “We look forward to working hand-in-hand with providers and payers, as well as our business partners, to make this innovative solution widely available to patients across the globe,” said Pierre Leurent, Voluntis founder and CEO, in a statement. Insulia is a prescription-only device that provides patients with insulin dose recommendations and educational coaching messages in response to blood glucose values and other diabetes-related data.
You are here: / / Insulia receives FDA clearance